EMFIB 250MG TABLET contains Gefitinib which belongs to the group of medicines called Antineoplastics. It is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating mutation of the EGFR-TK.
It is generally characterized by symptoms such as chest pain or discomfort, persistent cough, trouble breathing, wheezing, tiredness and difficulty while swallowing which may be diagnosed as any of its type as adenocarcinoma (cancer involving the outer part of the lung), squamous cell carcinoma (cancer occurring in the centre part of the lungs), and large cell carcinoma (cancer that can occur in any part of the lung).
Along with this treatment, your doctor might ask you to take liver function test to assess your liver function.
EMFIB 250MG TABLET is not recommended for use in patients allergic to Gefitinib. Before taking EMFIB 250MG TABLET, inform your doctor if you have other lung problems, liver, or kidney problems.
EMFIB 250MG TABLET is not recommended for use in pregnant and breastfeeding women. It is not recommended for use in children and adolescents (below 18 years). Consult your doctor before taking EMFIB 250MG TABLET.
The most common side effects of taking EMFIB 250MG TABLET are diarrhoea, vomiting, nausea, skin reactions, loss of appetite, weakness, and red or sore mouth. Consult with your doctor if any of the symptoms worsen.